专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2873419A4 PHARMACEUTICAL COMPOSITION COMPRISING AZATHIOPRINE AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING BRAIN TUMORS OR TEMODAL-RESISTANT GLIOBLASTOMAS 有权
标题翻译：硫唑嘌呤为有效防止或药物组合物脑肿瘤或治疗TEMODALRESISTENTEN胶质母细胞瘤
公开(公告)号：EP2873419A4
公开(公告)日：2015-06-10
申请号：EP13816643
申请日：2013-07-10
申请人： KOREA RES INST CHEM TECH , SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： CHO HEEYEONG , CHOI GILDON , PARK WOO KYU , JEONG DAE YOUNG , KIM HYEON YOUNG , LEE SUNKYUNG , NAM DO HYUN , SEOL HO JUN
IPC分类号： A61K31/52 , A61P35/00
CPC分类号： A61K31/52 , A61K31/495

2. 发明申请

WO2012050365A3 BIOMARKER FOR DIAGNOSING GLIOBLASTOMA OR PREDICTING PROGNOSIS OF GLIOBLASTOMA PATIENTS, AND USE THEREOF 审中-公开
公开(公告)号：WO2012050365A3
公开(公告)日：2012-11-01
申请号：PCT/KR2011007592
申请日：2011-10-12
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION , NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
发明人： NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： G01N33/57407
摘要： The present invention relates to a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients, and a use thereof, and more specifically, to an analysis method of a protein comprising the step of measuring the expression amount of the protein to provide the information necessary for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients by utilizing a protein selected from the group consisting of survivin, cyclinE, DCC, TGF-ß, CDC25B, Histone H1, p-EGFR, p-VEGFR2/3 and p16 as a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients. Since the proteins discovered through the analysis of the present invention can be applied to predict the prognosis of glioblastoma patients, a kit can be provided for predicting the prognosis of glioblastoma patients using the same and to apply the discovered proteins to develop a novel target therapy with respect to the proteins and an anticancer drug. As a result, the biomarker would also have a great ripple effect on the related industry fields, and is thus useful.

3. 发明申请

WO2012050365A2 BIOMARKER FOR DIAGNOSING GLIOBLASTOMA OR PREDICTING PROGNOSIS OF GLIOBLASTOMA PATIENTS, AND USE THEREOF 审中-公开
标题翻译：生物标志物用于诊断滑膜瘤或预测滑膜瘤患者的预后及其应用
公开(公告)号：WO2012050365A2
公开(公告)日：2012-04-19
申请号：PCT/KR2011007592
申请日：2011-10-12
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION , NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
发明人： NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： G01N33/57407
摘要： The present invention relates to a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients, and a use thereof, and more specifically, to an analysis method of a protein comprising the step of measuring the expression amount of the protein to provide the information necessary for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients by utilizing a protein selected from the group consisting of survivin, cyclinE, DCC, TGF-ß, CDC25B, Histone H1, p-EGFR, p-VEGFR2/3 and p16 as a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients. Since the proteins discovered through the analysis of the present invention can be applied to predict the prognosis of glioblastoma patients, a kit can be provided for predicting the prognosis of glioblastoma patients using the same and to apply the discovered proteins to develop a novel target therapy with respect to the proteins and an anticancer drug. As a result, the biomarker would also have a great ripple effect on the related industry fields, and is thus useful.
摘要翻译：本发明涉及用于诊断胶质母细胞瘤或预测胶质母细胞瘤患者的预后的生物标志物及其用途，并且更具体地涉及蛋白质的分析方法，所述方法包括测量蛋白质表达量以提供必要信息的步骤通过利用选自由生存素，细胞周期蛋白E，DCC，TGF-β，CDC25B，组蛋白H1，p-EGFR，p-VEGFR2 / 3和p16组成的组的蛋白质作为生物标志物来诊断胶质母细胞瘤或预测胶质母细胞瘤患者的预后诊断胶质母细胞瘤或预测胶质母细胞瘤患者的预后。由于通过本发明的分析发现的蛋白质可以用于预测成胶质细胞瘤患者的预后，因此可以提供试剂盒用于预测使用胶质母细胞瘤患者的成胶质细胞瘤患者的预后，并将所发现的蛋白质应用于开发新的靶向治疗尊重蛋白质和抗癌药物。因此，生物标志物也将在相关的工业领域产生巨大的连锁反应，因此是有用的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式